| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 8.16▼ | 8.23▼ | 8.23▼ | 8.22▼ | 7.95▲ |
| MA10 | 8.18▼ | 8.23▼ | 8.30▼ | 8.11▲ | 7.51▲ |
| MA20 | 8.22▼ | 8.31▼ | 8.33▼ | 7.87▲ | 6.15▲ |
| MA50 | 8.24▼ | 8.26▼ | 8.21▼ | 7.22▲ | 5.04▲ |
| MA100 | 8.29▼ | 8.19▼ | 7.95▲ | 5.80▲ | 5.95▲ |
| MA200 | 8.34▼ | 7.92▲ | 7.67▲ | 4.75▲ | 6.07▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.007▼ | -0.019▼ | -0.034▼ | 0.001▲ | 0.234▲ |
| RSI | 35.401▼ | 39.849▼ | 44.415▼ | 57.342▲ | 75.360▲ |
| STOCH | 15.995▼ | 47.530 | 28.771 | 61.673 | 81.466▲ |
| WILL %R | -86.667▼ | -85.227▼ | -85.714▼ | -40.558 | -14.644▲ |
| CCI | -59.670 | -126.275▼ | -112.389▼ | 48.690 | 105.194▲ |
|
Thursday, October 02, 2025 01:11 PM
The Company granted options to purchase 118,000 shares, in the aggregate, of Terns common stock to the new employees. The options have a 10-year term and an exercise price per share equal to $7.81, ...
|
|
Tuesday, September 30, 2025 05:50 AM
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...
|
|
Tuesday, September 30, 2025 03:52 AM
Terns Pharmaceuticals, Inc. is a clinical-stage biotech focused on oncology & obesity, with TERN-601 obesity program. Read why TERN stock is a Hold.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 13/10/25 | 8.16 | 8.3351 | 8.073 | 8.20 | 1,312,252 |
| 10/10/25 | 8.58 | 8.6214 | 8.08 | 8.15 | 953,316 |
| 09/10/25 | 8.29 | 8.54 | 8.285 | 8.50 | 823,957 |
| 08/10/25 | 8.04 | 8.42 | 7.976 | 8.26 | 760,278 |
| 07/10/25 | 8.40 | 8.44 | 7.98 | 7.99 | 1,246,401 |
| 06/10/25 | 8.54 | 8.7799 | 8.205 | 8.43 | 1,943,644 |
| 03/10/25 | 8.01 | 8.32 | 8.01 | 8.23 | 851,962 |
| 02/10/25 | 7.80 | 8.05 | 7.73 | 8.03 | 659,807 |
| 01/10/25 | 7.52 | 8.09 | 7.45 | 7.81 | 1,169,226 |
| 30/09/25 | 7.78 | 7.90 | 7.50 | 7.51 | 1,468,603 |
|
|
||||
|
|
||||
|
|